ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Clinical trials for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA explained in plain language.
Never miss a new study
Get alerted when new ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA trials appear
Sign up with your email to follow new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in preventing deadly blood clot relapses in japanese patients
Disease control CompletedThis study tested a drug called caplacizumab in 21 Japanese adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. Participants received caplacizumab alongside standard treatments like plasma exchange and steroids. The goa…
Matched conditions: ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Phase: PHASE2, PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Study reveals tricky platelet swings in blood disorder drug response
Knowledge-focused CompletedThis study looked back at 223 people with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab (Cablivi). The drug quickly normalizes platelet counts, but some patients experience a sharp rise then a dip, which might mislead doctors into giving unnecessar…
Matched conditions: ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:26 UTC